Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Feature

A-425619: A TRPV1 receptor antagonist with potential for the treatment of inflammatory, postoperative and arthritic pain

Posted on: 02 Aug 05

Summary

The worldwide analgesic market was worth $38 billion during the year 2002 and is expected to nearly double to $75 billion by the year 2010. The vanilloid receptor TRPV1 (VR1) has become an attractive molecular target for multiple sub-types of pain. Abbott researchers have recently described the development of A-425619

The worldwide analgesic market was worth $38 billion during the year 2002 and is expected to nearly double to $75 billion by the year 2010 (for a recent and in depth insight see Pain Therapeutics - Drugs, Markets and Companies). The vanilloid receptor TRPV1 (VR1) has now become an attractive molecular target for multiple sub-types of pain. Abbott researchers have recently described the development of A-425619, a low nanomolar TRPV1 antagonist. This molecule blocks heat hypersensitivity in a model of inflammatory pain as well as posoperative and arthritic algesia. Although A-425619 was demonstrated to have considerable potential as an anti-hyperalgesic agent and effect on neuropathic pain was not observed...[more]

Source LeadDiscovery

Featured on DailyUpdates-CNS Diseases

LeadDiscovery

Last updated on: 27/08/2010 11:40:18

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.